$FMI News

Last published 5y ago

5y agoFMI CLRTTwinStrand Biosciences Announces $50 Million Series B to Expand the Adoption of its Duplex Sequencing Technology in Applications Requiring the Highest Sensitivity and AccuracyBusiness WireTwinStrand's transformational improvements in DNA sequencing accuracy deliver 10,000x greater sensitivity, making it a crucial tool for genomic research and medicine Financing was led by Section 32 partner Michael Pellini, MD who has also joined t
5y agoATEC CMIIU FDMT ILMN+4Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of DirectorsGlobeNewswireSAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three in
8y agoFMIFoundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer ImmunotherapyBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure blood tumor mutational burden (bTMB) can help predict response to the anti-PD-L1 immunotherapy, atezolizumab, (TECENTRIQ®) in patients with previously treated non-small cell lung cancer (NSCLC). The study, published i ...
8y agoFMIFoundation Medicine and Guardant Health Agree to Settle Patent Infringement LawsuitBusiness WireCAMBRIDGE, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc. announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S. Patent No. 9,340,830. Under the terms of the settlement, the lawsuit and counterclaims, as well as challenges to the patent in inter partes review, ha ...
8y agoFMIFoundation Medicine to Present at Upcoming Investor ConferencesBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
8y agoFMIFoundation Medicine and Collaborators to Present New Data at ASCO 2018 Supporting Comprehensive Genomic Profiling (CGP) to Inform Personalized Approaches in Cancer CareBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated from its comprehensive genomic profiling (CGP) assays will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5, 2018 in Chicago. The company and its collaborators will present a total of 28 studies, including two oral presentations. Highlights ...
8y agoFMIFoundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with MerckBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop companion diagnostic tests for use with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy and the first approved immunotherapy for microsatellite instability (MSI) high or mismatch repair deficient solid tumors. The c ...
8y agoFMIFoundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)Business WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that under the Protecting Access to Medicare Act of 2014 (PAMA) the Centers for Medicare & Medicaid Services (CMS) approved new Advanced Diagnostic Laboratory Test (ADLT) status for FoundationOne CDx™. FoundationOne CDx is the first FDA-approved comprehensive genomic profiling assay for all solid tumors that ...
8y agoFMIFoundation Medicine Announces 2018 First Quarter Results and Recent HighlightsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included:
8y agoFMIFoundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced CancerBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profiling (CGP) suite of molecular information tests, further enhances support for the Co ...
8y agoFMIFoundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in ChinaBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., (NASDAQ:FMI), F. Hoffmann-La Roche Ltd (Roche) and DIAN Diagnostics Group, Co., Ltd. (DIAN), today announced a three-party collaboration to integrate Foundation Medicine’s comprehensive genomic profiling (CGP) assays into clinical patient care in mainland China. Under the collaboration:
8y agoFMIFoundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug AdministrationBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay. The new assay will include more than 70 genes and genomic biomarkers for microsatell ...
8y agoFMIFoundation Medicine Announces Timing for First Quarter 2018 Financial Results and Conference CallBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2018 will be released on Wednesday, May 2, 2018. The management team will host a conference call on Wednesday, May 2, 2018, at 4:30 p.m. ET to discuss the company's financial results and recent developments. The call can be accessed by dia ...
8y agoFMIFoundation Medicine and its Collaborators Present New Findings Supporting Tissue- and Blood-based Comprehensive Genomic Profiling (CGP) to Inform Targeted and Cancer Immunotherapy Treatment StrategiesBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the presentation of new findings at the American Association for Cancer Research (AACR) Annual Meeting. The data supports the use of both tissue- and blood-based comprehensive genomic profiling (CGP) to advance personalized cancer care and inform the use of targeted and immunotherapy treatment approaches. Pre ...
8y agoFMIFoundation Medicine Announces Commercial Availability of FoundationOne CDx™, the First FDA-Approved Comprehensive Genomic Profiling Assay for All Solid Tumors Incorporating Multiple Companion DiagnosticsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that FoundationOne CDx™, the first U.S. Food and Drug Administration (FDA) approved comprehensive genomic profiling (CGP) assay for all solid tumors incorporating multiple companion diagnostics, is now available in the United States. FoundationOne CDx is a first-of-its-kind test for individuals with advanced ...
8y agoFMIFoundation Medicine Announces Final National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS), Including Coverage for FoundationOne CDx™ Across All Solid TumorsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the Centers for Medicare & Medicaid Services (CMS) issued a final National Coverage Determination (NCD) for patients who receive next generation sequencing (NGS) testing with an assay that meets the coverage criteria. Medicare and Medicare Advantage patients who receive testing with FoundationOne CDx™, t ...
8y agoFMIFoundation Medicine Advances Patient Access to Precision Medicine; Pursues Regulatory Approval for FoundationOne CDx™ in JapanBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), one of Japan's leading research-based pharmaceutical companies and a member of the Roche Group, will broaden patient access to Foundation Medicine’s comprehensive genomic profiling (CGP) services for individuals with advanced cancer. Specifically, Chugai has ...
8y agoFMIFoundation Medicine and Guardant Health Agree to Resolve False Advertising LawsuitBusiness WireCAMBRIDGE, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc. announced an agreement to settle false advertising challenges that the companies had filed against each other under the Lanham Act related to advertising for their respective liquid genomic profiling assays. Under the terms of the settlement, the lawsuit and counterclaims will ...
8y agoFMIFoundation Medicine to Present at Cowen and Company’s 38th Annual Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at Cowen & Company’s 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.m. ET in Boston.
8y agoFMIFoundation Medicine Announces 2017 Fourth Quarter and Year-End Results, Recent Highlights and 2018 OutlookBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2017. Highlights for the quarter and year included:
8y agoFMIFoundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference CallBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018. The management team will host a conference call on Wednesday, March 7, 2018, at 4:30 p.m. ET to discuss the company's financial results and recent developments. The call can b ...
8y agoBMY FMIPivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)Business WirePRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of progression-free survival (PFS) with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients whose tumors have high (≥10 mutations/megabase, m ...
8y agoFMIFoundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial EnrollmentBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) and the European Organisation for Research and Treatment of Cancer (EORTC) announced today a collaboration in which Foundation Medicine’s comprehensive genomic profiling (CGP) tests will be used to inform patient eligibility for oncology clinical trials through the EORTC’s Screening Patients for Efficient Clinical Trial Acce ...
8y agoFMI PFEFoundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer’s Oncology PortfolioBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company has entered into a broad partnership with Pfizer Inc. (NYSE: PFE). The partnership focuses on development, regulatory support and commercialization of companion diagnostics (CDx) that will be included in updates to FoundationOne CDx™. FoundationOne CDx is Foundation Medicine’s FDA-approved co ...
8y agoFMIFoundation Medicine Reports Preliminary 2017 ResultsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine (NASDAQ:FMI) today announced preliminary unaudited total revenue of approximately $48.9 million for the fourth quarter of 2017 and approximately $152.9 million for the full year ended December 31, 2017, representing a 70% and 31% increase from the $28.8 million and $116.9 million recorded in the fourth quarter and full year ended December 31, ...
8y agoFMIFoundation Medicine to Present at the 36th Annual J.P. Morgan Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 3:30 p.m. PST in San Francisco. Additionally, Troy Cox will participate in a panel discussion focused on the Food & Drug Administration and Centers for Medicare and Medicaid Services ...
8y agoFMIFoundation Medicine and Collaborators to Present New Data at the American Society of Hematology (ASH) Annual Meeting that Supports Use of FoundationOne®Heme to Advance Personalized Medicine in Blood CancersBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated with FoundationOne®Heme, its comprehensive genomic profiling (CGP) assay for hematologic malignancies and sarcomas, will be presented at the American Society of Hematology (ASH) Annual Meeting. Data from a broad range of blood cancers, including acute myeloid leukemia (AML), myeloproli ...
8y agoFMIFDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion DiagnosticsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx™, the company’s comprehensive companion diagnostic test for solid tumors. FoundationOne CDx is intended for use by health care professionals to help inform cancer treatment management in accordance with professional guidelines for pat ...
9y agoFMIFoundation Medicine Announces 2017 Third Quarter Results and Recent HighlightsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its third quarter ended September 30, 2017. Results and business highlights for the quarter included:
9y agoFMIFoundation Medicine to Present Validation for FoundationOne CDx™, a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer CareBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company will present validation data for FoundationOne CDx, its comprehensive genomic profiling assay, at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC). Data demonstrated high concordance with multiple companion diagnostics and other si ...
9y agoFMIFoundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference CallBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's third quarter ended September 30, 2017 will be released on Wednesday, November 1, 2017. The management team will host a conference call on Wednesday, November 1, 2017, at 4:30 p.m. ET to discuss the company's financial results and recent developments. The call can be a ...
9y agoFMIFoundation Medicine Appoints Tom Civik as Chief Commercial OfficerBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of Tom Civik to the role of chief commercial officer. Mr. Civik brings to Foundation Medicine more than two decades of commercial and operational experience with global biopharmaceutical organizations, most recently having served as a vice president and officer for Genentech, as well as previo ...
9y agoFMIFoundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy AssayBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it received approval from the New York State (NYS) Clinical Laboratory Evaluation Program (CLEP) for its FoundationACT® blood-based circulating tumor DNA (ctDNA) assay. The CLEP regulates and seeks to ensure the accuracy and reliability of test results in clinical laboratories located in or accepting spe ...
9y agoFMIFoundation Medicine to Present Validation Data for Its Assay Measuring Tumor Mutational Burden in Blood (bTMB), a New, Non-Invasive Predictor of Response to ImmunotherapyBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced presentations at the European Society for Medical Oncology (ESMO) Annual Meeting highlighting validation data for its novel assay to measure tumor mutational burden from blood (bTMB). These presentations will highlight retrospective data analysis from Roche/Genentech’s Phase II POPLAR and Phase III OAK studie ...
9y agoFMIFoundation Medicine to Present at the 2017 Wells Fargo Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the 2017 Wells Fargo Healthcare Conference in Boston on Thursday, September 7, 2017, at 10:35 a.m. ET.
9y agoFMIEQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Foundation Medicine, Inc.Business WireNEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Foundation Medicine, Inc. (“Foundation Medicine”) (NASDAQ:FMI) violated federal securities laws.
9y agoFMIThe Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Foundation Medicine, Inc.Business WireNEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Foundation Medicine, Inc. (“Foundation Medicine”) (NASDAQ: FMI) violated federal securities laws.
9y agoFMIFoundation Medicine Announces 2017 Second Quarter Results and Recent HighlightsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its second quarter ended June 30, 2017. Results and business highlights for the quarter included:
9y agoFMIFoundation Medicine Announces Timing for Second Quarter 2017 Financial Results and Conference CallBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's second quarter ended June 30, 2017 will be released on Tuesday, August 1, 2017. The management team will host a conference call on Tuesday, August 1, 2017, at 4:30 p.m. ET to discuss the company's financial results and recent developments. The call can be accessed by d ...
9y agoFMIASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) StudyBusiness WireALEXANDRIA, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The American Society of Clinical Oncology, Inc. (ASCO) and Foundation Medicine (NASDAQ: FMI) today announced entry into an agreement to create efficiencies for research sites participating in ASCO’s TAPUR™ Study in identifying potential participants for the study. ASCO is announcing that reports from Foundation Medicine’s comprehensive genomic p ...
9y agoFMIFoundation Medicine to Identify Patients Eligible for National Cancer Institute’s NCI-MATCH (Molecular Analysis for Therapy Choice) StudyBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine (NASDAQ: FMI) today announced a collaboration with the National Cancer Institute (NCI) and ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) for their precision medicine cancer trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131). This ongoing study is evaluating the benefit of genomically-guided treatments targeting specific alt ...
9y agoFMIFoundation Medicine to Present at Upcoming Investor ConferencesBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
9y agoFMIFoundation Medicine and Its Collaborators to Present New Data at ASCO 2017 Supporting the Integration of Comprehensive Genomic Profiling (CGP) in Personalized Clinical Care in OncologyBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that data from its suite of comprehensive genomic profiling (CGP) assays, including FoundationOne®, FoundationACT® liquid biopsy, FoundationOne® Heme, and FoundationFocus™ CDxBRCA will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2017 in Chicago. The compa ...
9y agoFMIFoundation Medicine Announces 2017 First Quarter Results and Recent HighlightsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2017. Results and business highlights for the quarter included:
9y agoFMIFoundation Medicine Announces Timing for First Quarter 2017 Financial Results and Conference CallBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2017 will be released on Tuesday, May 9, 2017. The management team will host a conference call on Tuesday, May 9, 2017, at 4:30 p.m. ET to discuss the company's financial results and recent developments. The call can be accessed by dialing ...
9y agoBMY FMIBristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy AgentsBusiness WireNEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across cli ...
9y agoFMIFoundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company’s Comprehensive Genomic Profiling AssayBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it has received payment from Palmetto GBA, the Company’s Medicare Administrative Contractor (MAC) in North Carolina, for its FoundationOne comprehensive genomic profiling assay when used in the clinical course of care for individuals in the United States with Stage IIIB/IV non-small cell lung cancer (NSC ...
9y agoFMIFoundation Medicine to Present at Cowen and Company’s 37th Annual Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at Cowen & Company’s 37th Annual Healthcare Conference on Monday, March 6, 2017, at 4:40 p.m. ET in Boston.
9y agoFMIFoundation Medicine's (FMI) CEO Troy Cox on Q4 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoFMIFoundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 OutlookBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2016. Highlights for the quarter and year included: